Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets

Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, Kartikeya Bhardwaj, Stacey E. P. Joosten, Takaaki Fujii, Ken Shirabe, Andrew R. Green, Ian O. Ellis, Emad A. Rakha, Nigel P. Mongan, David M. Heery, Wilbert Zwart, Steffi Oesterreich, Simon J. Johnston
doi: https://doi.org/10.1101/2020.01.24.20018622

Data Availability

The datasets generated and/or analysed during the current study are available via the CBioportal online portal (http://www.cbioportal.org) and in the Genome-Phenome Archives EGAS00000000098 and phs000178.

https://ega-archive.org/studies/EGAS00000000098

https://ega-archive.org/studies/phs000178

Back to top
Posted January 27, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, Kartikeya Bhardwaj, Stacey E. P. Joosten, Takaaki Fujii, Ken Shirabe, Andrew R. Green, Ian O. Ellis, Emad A. Rakha, Nigel P. Mongan, David M. Heery, Wilbert Zwart, Steffi Oesterreich, Simon J. Johnston
medRxiv 2020.01.24.20018622; doi: https://doi.org/10.1101/2020.01.24.20018622
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area